Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 3554 | 10.64 |
09:34 ET | 3915 | 10.69 |
09:38 ET | 100 | 10.79 |
09:39 ET | 1700 | 10.765 |
09:41 ET | 280 | 10.84 |
09:43 ET | 430 | 10.81 |
09:50 ET | 1344 | 10.86 |
09:54 ET | 200 | 10.9 |
09:57 ET | 1199 | 10.79 |
10:01 ET | 200 | 10.735 |
10:03 ET | 500 | 10.7441 |
10:10 ET | 100 | 10.83 |
10:12 ET | 349 | 10.795 |
10:14 ET | 200 | 10.77 |
10:15 ET | 100 | 10.795 |
10:21 ET | 4427 | 10.615 |
10:24 ET | 3008 | 10.61 |
10:28 ET | 400 | 10.66 |
10:30 ET | 122 | 10.6639 |
10:32 ET | 367 | 10.684 |
10:33 ET | 200 | 10.69 |
10:35 ET | 400 | 10.7 |
10:37 ET | 613 | 10.69 |
10:39 ET | 300 | 10.66 |
10:42 ET | 600 | 10.66 |
10:44 ET | 100 | 10.69 |
10:48 ET | 1365 | 10.635 |
10:50 ET | 200 | 10.635 |
10:55 ET | 1312 | 10.59 |
10:57 ET | 3502 | 10.6 |
11:04 ET | 800 | 10.645 |
11:08 ET | 400 | 10.63 |
11:11 ET | 1400 | 10.61 |
11:13 ET | 223 | 10.64 |
11:15 ET | 600 | 10.64 |
11:18 ET | 700 | 10.62 |
11:20 ET | 695 | 10.62 |
11:22 ET | 1600 | 10.6 |
11:27 ET | 200 | 10.525 |
11:29 ET | 678 | 10.5 |
11:31 ET | 150 | 10.47 |
11:33 ET | 680 | 10.5 |
11:38 ET | 562 | 10.419448 |
11:40 ET | 230 | 10.4 |
11:42 ET | 1146 | 10.3713 |
11:44 ET | 300 | 10.335 |
11:54 ET | 261 | 10.395 |
12:00 ET | 100 | 10.4 |
12:02 ET | 1862 | 10.33 |
12:03 ET | 200 | 10.3262 |
12:05 ET | 3265 | 10.38 |
12:12 ET | 100 | 10.35 |
12:14 ET | 100 | 10.35 |
12:18 ET | 900 | 10.31 |
12:23 ET | 500 | 10.37 |
12:27 ET | 300 | 10.4 |
12:32 ET | 100 | 10.44 |
12:34 ET | 536 | 10.41 |
12:36 ET | 400 | 10.44 |
12:38 ET | 769 | 10.39 |
12:39 ET | 300 | 10.37 |
12:41 ET | 1715 | 10.33 |
12:43 ET | 612 | 10.36 |
12:45 ET | 200 | 10.355 |
12:54 ET | 1100 | 10.3168 |
12:56 ET | 680 | 10.28 |
01:12 ET | 1471 | 10.24 |
01:14 ET | 100 | 10.22 |
01:24 ET | 600 | 10.22 |
01:30 ET | 2500 | 10.17 |
01:37 ET | 100 | 10.165 |
01:39 ET | 7510 | 10.225 |
01:42 ET | 1695 | 10.16 |
01:46 ET | 499 | 10.1 |
01:48 ET | 900 | 10.09 |
01:50 ET | 834 | 10.12 |
01:51 ET | 1100 | 10.175 |
01:55 ET | 1676 | 10.185 |
01:57 ET | 260 | 10.19 |
02:00 ET | 918 | 10.1771 |
02:04 ET | 434 | 10.185 |
02:08 ET | 648 | 10.15 |
02:13 ET | 4400 | 10.13 |
02:24 ET | 3691 | 10.008763 |
02:26 ET | 300 | 9.99 |
02:27 ET | 313 | 10.01 |
02:29 ET | 500 | 10.025 |
02:33 ET | 100 | 10.025 |
02:36 ET | 332 | 10.05 |
02:38 ET | 100 | 10.08 |
02:40 ET | 3341 | 10.12 |
02:42 ET | 100 | 10.15 |
02:44 ET | 4883 | 10.19 |
02:45 ET | 404 | 10.185 |
02:47 ET | 10954 | 10.16 |
02:49 ET | 500 | 10.18 |
02:51 ET | 100 | 10.2 |
02:54 ET | 909 | 10.195 |
02:56 ET | 325 | 10.189 |
03:00 ET | 700 | 10.19 |
03:02 ET | 1207 | 10.18 |
03:03 ET | 600 | 10.18 |
03:05 ET | 522 | 10.22 |
03:07 ET | 447 | 10.225 |
03:09 ET | 100 | 10.225 |
03:12 ET | 100 | 10.225 |
03:14 ET | 967 | 10.175 |
03:20 ET | 319 | 10.1713 |
03:21 ET | 100 | 10.185 |
03:25 ET | 1200 | 10.22 |
03:27 ET | 400 | 10.215 |
03:30 ET | 1895 | 10.21 |
03:34 ET | 1168 | 10.18 |
03:36 ET | 280 | 10.2 |
03:41 ET | 200 | 10.22 |
03:43 ET | 2333 | 10.2003 |
03:45 ET | 100 | 10.195 |
03:50 ET | 682 | 10.2 |
03:52 ET | 3312 | 10.22 |
03:54 ET | 5186 | 10.28 |
03:56 ET | 2780 | 10.29 |
03:57 ET | 3284 | 10.29 |
03:59 ET | 68736 | 10.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 697.7M | -5.8x | --- |
Rapport Therapeutics Inc | 695.0M | -11.6x | --- |
ProKidney Corp | 692.3M | -3.3x | --- |
Savara Inc | 691.3M | -9.8x | --- |
Scholar Rock Holding Corp | 685.9M | -3.6x | --- |
MBX Biosciences Inc | 713.1M | -17.5x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $723.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.